United Therapeutics Net Income
| UTHR Stock | USD 473.12 12.24 2.52% |
As of the 10th of February, United Therapeutics has the Coefficient Of Variation of 972.13, semi deviation of 1.17, and Risk Adjusted Performance of 0.086. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of United Therapeutics, as well as the relationship between them. Please validate United Therapeutics coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if United Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 473.12 per share. Given that United Therapeutics has jensen alpha of 0.0865, we advise you to double-check United Therapeutics's current market performance to make sure the company can sustain itself at a future point.
United Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 5.6858 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 1.4 B | 1.4 B | |
| Net Income Applicable To Common Shares | 836.4 M | 878.2 M | |
| Net Income From Continuing Ops | 1.4 B | 1.4 B | |
| Net Income Per Share | 23.80 | 24.99 | |
| Net Income Per E B T | 0.89 | 0.92 |
United | Net Income | Build AI portfolio with United Stock |
Evaluating United Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into United Therapeutics's fundamental strength.
Latest United Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of United Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in United Therapeutics financial statement analysis. It represents the amount of money remaining after all of United Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is United Therapeutics' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in United Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 1.2 B | 10 Years Trend |
|
Net Income |
| Timeline |
United Net Income Regression Statistics
| Arithmetic Mean | 588,666,544 | |
| Geometric Mean | 409,001,462 | |
| Coefficient Of Variation | 76.59 | |
| Mean Deviation | 349,394,694 | |
| Median | 514,800,000 | |
| Standard Deviation | 450,833,081 | |
| Sample Variance | 203250.5T | |
| Range | 1.5B | |
| R-Value | 0.80 | |
| Mean Square Error | 77109T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | 71,663,922 | |
| Total Sum of Squares | 3252007.5T |
United Net Income History
Other Fundumenentals of United Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
United Therapeutics Net Income component correlations
United Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for United Therapeutics is extremely important. It helps to project a fair market value of United Stock properly, considering its historical fundamentals such as Net Income. Since United Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of United Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of United Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does United have expansion opportunities? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating United Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 0.121 | Earnings Share 25.69 | Revenue Per Share | Quarterly Revenue Growth 0.068 | Return On Assets |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, United Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
United Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to United Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of United Therapeutics.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in United Therapeutics on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding United Therapeutics or generate 0.0% return on investment in United Therapeutics over 90 days. United Therapeutics is related to or competes with Incyte, Genmab AS, Royalty Pharma, Quest Diagnostics, Zimmer Biomet, Tenet Healthcare, and Illumina. United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products t... More
United Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure United Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess United Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.29 | |||
| Information Ratio | 0.0231 | |||
| Maximum Drawdown | 5.21 | |||
| Value At Risk | (1.99) | |||
| Potential Upside | 2.0 |
United Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for United Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as United Therapeutics' standard deviation. In reality, there are many statistical measures that can use United Therapeutics historical prices to predict the future United Therapeutics' volatility.| Risk Adjusted Performance | 0.086 | |||
| Jensen Alpha | 0.0865 | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 0.022 | |||
| Treynor Ratio | 0.3408 |
United Therapeutics February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.086 | |||
| Market Risk Adjusted Performance | 0.3508 | |||
| Mean Deviation | 1.02 | |||
| Semi Deviation | 1.17 | |||
| Downside Deviation | 1.29 | |||
| Coefficient Of Variation | 972.13 | |||
| Standard Deviation | 1.23 | |||
| Variance | 1.52 | |||
| Information Ratio | 0.0231 | |||
| Jensen Alpha | 0.0865 | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 0.022 | |||
| Treynor Ratio | 0.3408 | |||
| Maximum Drawdown | 5.21 | |||
| Value At Risk | (1.99) | |||
| Potential Upside | 2.0 | |||
| Downside Variance | 1.66 | |||
| Semi Variance | 1.37 | |||
| Expected Short fall | (1.04) | |||
| Skewness | (0.20) | |||
| Kurtosis | (0.64) |
United Therapeutics Backtested Returns
Currently, United Therapeutics is very steady. United Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0398, which indicates the firm had a 0.0398 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for United Therapeutics, which you can use to evaluate the volatility of the company. Please validate United Therapeutics' Coefficient Of Variation of 972.13, risk adjusted performance of 0.086, and Semi Deviation of 1.17 to confirm if the risk estimate we provide is consistent with the expected return of 0.0487%. United Therapeutics has a performance score of 3 on a scale of 0 to 100. The entity has a beta of 0.34, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, United Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding United Therapeutics is expected to be smaller as well. United Therapeutics right now has a risk of 1.22%. Please validate United Therapeutics maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if United Therapeutics will be following its existing price patterns.
Auto-correlation | -0.41 |
Modest reverse predictability
United Therapeutics has modest reverse predictability. Overlapping area represents the amount of predictability between United Therapeutics time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of United Therapeutics price movement. The serial correlation of -0.41 indicates that just about 41.0% of current United Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.41 | |
| Spearman Rank Test | -0.65 | |
| Residual Average | 0.0 | |
| Price Variance | 129.63 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
United Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, United Therapeutics reported net income of 1.2 B. This is 250.18% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 109.31% lower than that of the firm.
United Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses United Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics of similar companies.United Therapeutics is currently under evaluation in net income category among its peers.
United Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, United Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to United Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
United Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in United Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of United Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing United Therapeutics' value.| Shares | Dimensional Fund Advisors, Inc. | 2025-06-30 | 573.7 K | Deerfield Management Co | 2025-06-30 | 540.6 K | Pacer Advisors, Inc. | 2025-06-30 | 509.7 K | Caisse De Depot Et Placement Du Quebec | 2025-06-30 | 482.8 K | Norges Bank | 2025-06-30 | 474.9 K | Northern Trust Corp | 2025-06-30 | 452.2 K | Fmr Inc | 2025-06-30 | 424.2 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 397.5 K | Victory Capital Management Inc. | 2025-06-30 | 396.7 K | Blackrock Inc | 2025-06-30 | 5.3 M | Vanguard Group Inc | 2025-06-30 | 4.4 M |
United Fundamentals
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.41 % | ||||
| Operating Margin | 0.49 % | ||||
| Current Valuation | 17.79 B | ||||
| Shares Outstanding | 43.06 M | ||||
| Shares Owned By Insiders | 1.85 % | ||||
| Shares Owned By Institutions | 98.75 % | ||||
| Number Of Shares Shorted | 1.78 M | ||||
| Price To Earning | 23.49 X | ||||
| Price To Book | 3.17 X | ||||
| Price To Sales | 6.84 X | ||||
| Revenue | 2.88 B | ||||
| Gross Profit | 2.77 B | ||||
| EBITDA | 1.65 B | ||||
| Net Income | 1.2 B | ||||
| Cash And Equivalents | 2.26 B | ||||
| Cash Per Share | 49.55 X | ||||
| Total Debt | 300 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 8.10 X | ||||
| Book Value Per Share | 153.61 X | ||||
| Cash Flow From Operations | 1.33 B | ||||
| Short Ratio | 3.98 X | ||||
| Earnings Per Share | 25.69 X | ||||
| Price To Earnings To Growth | 1.43 X | ||||
| Target Price | 531.25 | ||||
| Number Of Employees | 1.3 K | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 21.4 B | ||||
| Total Asset | 7.36 B | ||||
| Retained Earnings | 7.22 B | ||||
| Working Capital | 3.14 B | ||||
| Current Asset | 1.28 B | ||||
| Current Liabilities | 440.82 M | ||||
| Net Asset | 7.36 B |
About United Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with United Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against United Stock
| 0.62 | KRRO | Frequency Therapeutics | PairCorr |
| 0.53 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.5 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.49 | EVGN | Evogene | PairCorr |
| 0.48 | QSI | QuantumSi | PairCorr |
The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.
The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.